• SARS-CoV-2

    ELISA test systems from EUROIMMUN

Anti-SARS-CoV-2 ELISA IgG

Customer comments and testimonials about this ELISA

ProductIg classFormatIncluded controlsOrder no.Status
ELISA IgG96 x 01pos. control, neg. controlEI 2606-9601 GCE-marked

Performance data

Days after onset of symptoms or pos. direct detection nSensitivity*
> 10-201275.0%
≥ 211693.8%

*Borderline samples were evaluated as positive.

It is possible that no antibodies have formed yet in the persons who tested negative. In some isolated cases the onset of antibody secretion was detected only after a period of 4 – 6 weeks post onset of symptoms.

Paneln Specificity* Specificity**
Blood donors849 98.7% 99.5%
Pregnant women200 99.5% 99.5%
Children90 100% 100%
Older patients97 100% 100%
Other human coronaviruses29 100% 100%
Influenza
(fr. vaccinated, incl. follow ups)
40 100% 100%
Acute EBV infection &
heterophile antibodies
22 100% 100%
Rheumatoid factor40 100% 100%
Total136799.1% 99.6%

*Borderline samples were evaluated as positive.

**Borderline samples were evaluated as negative.


Anti-SARS-CoV-2 NCP ELISA

  • Antigen: modified nucleocapsid protein (NCP) – highly specific due to removal of unspecific epitopes
  • To support the diagnosis of COVID-19 and detect past infections with SARS-CoV-2
  • Use for collection of epidemiological data

   

ProductIg classFormatIncluded controlsOrder no.Status
ELISA IgG96 x 01pos. control, neg. controlEI 2606-9601-2 GCE-marked

Performance data

Days after onset of symptoms or pos. direct detectionnSensitivity*
> 10-20887.5%
≥ 211586.7%

*Borderline samples were evaluated as positive.

Paneln Specificity* Specificity**
Blood donors849 99.4% 99.8%
Pregnant women99 100% 100%
Children90 100% 100%
Older patients with non-
inflammatory skin diseases
97 97,9% 99,0%
Other human coronaviruses46 100% 100%
Influenza
(fr. vaccinated, incl. follow ups)
40 100% 100%
Acute EBV infection &
heterophile antibodies
22 100% 100%
Rheumatoid factor40 100% 100%
Total128399.5% 99.8%

*Borderline samples were evaluated as positive.

**Borderline samples were evaluated as negative.


Anti-SARS-CoV-2 ELISA IgA

  • Antigen: S1 domain of the spike protein
  • Suitable for monitoring of a developing immune response after positive direct detection

   

ProductIg classFormatIncluded controlsOrder no.Status
ELISAIgA96 x 01pos. control, neg. controlEI 2606-9601 ACE-marked

Performance data

Days after onset of symptoms or pos. direct detectionnSensitivity*
> 10-201291.7%
≥ 2116100.0%

*Borderline samples were evaluated as positive.

n Specificity* Specificity**
1241

88.2%

92.4%

*Borderline samples were evaluated as positive.

**Borderline samples were evaluated as negative.


Options for automated processing of the EUROIMMUN ELISA

1. EUROIMMUN Automation Solutions:

EUROLabWorkstation ELISA, Analyzer I, Analyzer I-2P and Sprinter XL

For further information on our automation options, please contact our experts of product management for instruments and software.


2. Processing on all common open ELISA platforms